BioMarin Pharmaceutical Inc. (BMRN) entered a merger agreement on May 16, 2025, to acquire Inozyme Pharma, Inc. (INZY) through a cash tender offer valued at $270 million.
Under the terms of the agreement, BioMarin will commence a cash tender offer to acquire all of the outstanding shares of Inozyme common stock at $4 per share, representing a premium of 181.69% from the stock’s last close.